



UNIVERSITÀ
DEGLI STUDI
FIRENZE

FLORE

Repository istituzionale dell'Università degli Studi di Firenze

Cardiovascular risk assessment in low-resource settings

Questa è la Versione finale referata (Post print/Accepted manuscript) della seguente pubblicazione:

Original Citation:

Cardiovascular risk assessment in low-resource settings / Pietro A. Modesti; Piergiuseppe Agostoni; Charles Agyemang; Sanjay Basu; Athanase Benetos; Francesco P. Cappuccio; Antonio Ceriello; Stefano Del Prato; Robert Kalyesubula; Eoin O'Brien; Michael O. Kilama; Stefano Perlini; Eugenio Picano; Gianpaolo Reboldi; Giuseppe Remuzzi; David Stuckler; Marc Twagirumukiza; Luc M. Van

Availability:

The webpage <https://hdl.handle.net/2158/861593> of the repository was last updated on

Published version:

DOI: 10.1097/HJH.000000000000125

Terms of use:

Open Access

La pubblicazione è resa disponibile sotto le norme e i termini della licenza di deposito, secondo quanto stabilito dalla Policy per l'accesso aperto dell'Università degli Studi di Firenze (<https://www.sba.unifi.it/upload/policy-oa-2016-1.pdf>)

Publisher copyright claim:

La data sopra indicata si riferisce all'ultimo aggiornamento della scheda del Repository FloRe - The above-mentioned date refers to the last update of the record in the Institutional Repository FloRe

(Article begins on next page)

Cardiovascular risk assessment in low-resource settings: a consensus document of the European Society of Hypertension Working Group on Hypertension and Cardiovascular Risk in Low Resource Settings

Pietro A. Modesti^a, Piergiuseppe Agostoni^b, Charles Agyemang^c, Sanjay Basu^d, Athanase Benetos^e, Francesco P. Cappuccio^f, Antonio Ceriello^g, Stefano Del Prato^h, Robert Kalyesubulaⁱ, Eoin O'Brien^j, Michael O. Kilama^k, Stefano Perlini^l, Eugenio Picano^m, Gianpaolo Reboldiⁿ, Giuseppe Remuzzi^o, David Stuckler^p, Marc Twagirumukiza^q, Luc M. Van Bortel^r, Ghassan Watfa^r, Dong Zhao^s, and Gianfranco Parati^{t,u}, for the ESH Working Group on Hypertension and Cardiovascular Risk in Low Resource Settings

The Global Burden of Diseases, Injuries, and Risk Factors Study 2010 confirms ischemic heart disease and stroke as the leading cause of death and that hypertension is the main associated risk factor worldwide. How best to respond to the rising prevalence of hypertension in resource-deprived settings is a topic of ongoing public-health debate and discussion. In low-income and middle-income countries, socioeconomic inequality and cultural factors play a role both in the development of risk factors and in the access to care. In Europe, cultural barriers and poor communication between health systems and migrants may limit migrants from receiving appropriate prevention, diagnosis, and treatment. To use more efficiently resources available and to make treatment cost-effective at the patient level, cardiovascular risk approach is now recommended. In 2011, The European Society of Hypertension established a Working Group on 'Hypertension and Cardiovascular risk in low resource settings', which brought together cardiologists, diabetologists, nephrologists, clinical trialists, epidemiologists, economists, and other stakeholders to review current strategies for cardiovascular risk assessment in population studies in low-income and middle-income countries, their limitations, possible improvements, and future interests in screening programs. This report summarizes current evidence and presents highlights of unmet needs.

Keywords: cardiovascular risk, global cardiovascular and cerebrovascular health, low-income and middle-income countries, migrants and minority groups

Abbreviations: ACR, albuminuria to creatininuria ratio; CKD, chronic kidney disease; CVD, cardiovascular disease; ESH, European Society of Hypertension; GBD, Global Burden of Disease; LMIC, low-income and middle-income countries; STEPS, STEPwise Approach to Stroke Surveillance

HYPERTENSION IN A GLOBAL PERSPECTIVE

According to the Global Burden of Disease (GBD) 2010 study, the most comprehensive and comparable assessment of mortality and loss of health to date [1], cardiovascular disease (CVD) is the leading cause of death worldwide, 80% of the 16.7 million deaths due to CVD occur in low-income and middle-income countries (LMICs) and hypertension is now the leading associated

Journal of Hypertension 2014, 31:000–000

^aDepartment of Clinical and Experimental Medicine, University of Florence, Florence, ^bCentro Cardiologico Monzino, IRCCS, Milan, Italy, ^cDepartment of Public Health, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands, ^dUniversity of California, San Francisco, California, USA, ^eINSERM UMR S1116, Université de Lorraine, Vandoeuvre-les-Nancy, Nancy, France, ^fUniversity of Warwick, Warwick Medical School, and University Hospitals Coventry & Warwickshire NHS Trust, Coventry, UK, ^gInstitut d'Investigacions Biomèdiques August Pi i Sunyer IDIBAPS, and Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Barcelona, Spain, ^hSection of Metabolic Diseases and Diabetes, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ⁱMakerere University, Kampala, Uganda, ^jThe Conway Institute, University College Dublin, Dublin, Ireland, ^kBenedict Medical Center, Kampala, Uganda, ^lClinica Medica II, University of Pavia, Pavia, ^mInstitute of Clinical Physiology, CNR, Pisa, ⁿDepartment of Internal Medicine, University of Perugia, Perugia, ^oIRCCS-Istituto di Ricerche Farmacologiche 'Mario Negri', Bergamo, Italy, ^pDepartment of Sociology, University of Oxford, Oxford, UK, ^qFaculty of Medicine and Health Sciences, Heymans Institute of Pharmacology, Ghent University, Ghent, Belgium, ^rDepartment of Geriatrics, CHU Nancy, Nancy, France, ^sBeijing Institute of Heart, Lung and Blood Vessel Diseases, Capital Medical University, Beijing Anzhen Hospital, Beijing, China, ^tDepartment of Health Sciences, University of Milano-Bicocca and ^uDepartment of Cardiology, S. Luca Hospital, IRCCS Istituto Auxologico Italiano, Milan, Italy

Correspondence to Professor Pietro A. Modesti, (Chairman of the Working Group), Department of Clinical and Experimental Medicine, University of Florence, Florence, Italy. Tel: +39 055 7949376; e-mail: pamodesti@unifi.it

Received 21 September 2013 **Revised** 9 January 2014 **Accepted** 9 January 2014
J Hypertens 32:000–000 © 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially.

DOI: 10.1097/HJH.0000000000000125

risk factor [1,2]. High blood pressure (BP) accounts for 9.4 million (95% UI 8.6 million to 10.1 million) deaths and 7.0% (6.2–7.7) of global disability-adjusted life years (DALYs), more than elevated BMI, fasting plasma glucose, and total cholesterol combined [2].

As of 2008, almost 1 billion people have uncontrolled hypertension worldwide [3]. The African region has the highest prevalence rate, 46% of adults aged 25 and above, whereas the Americas have the lowest prevalence, at 35%. In contrast with other CVD risks such as high BMI, the burden of hypertension is greater in lower income countries than higher income settings [3,4]. In an urban African setting, the stroke death rate (a proxy of hypertension prevalence and control) was reported to be five-fold higher than that in England [5,6]. According to WHO data, age-standardized death rate (per 100 000 population) is 141 in the African region and 93 in the European region [7]. Multiple risk factors positively interact to exacerbate CVD risks. Hypertension, for example, combined with unhealthy diets and lack of physical activity (sodium and alcohol consumption, high BMI, and low physical activity), has a multiplicative negative effect on CVD mortality and DALYs [2]. A substantial part of the CVD risk of death and DALYs attributable to these factors is not also exacerbated by, but also mediated through high BP [2]. In LMICs, overweight or obesity was associated with hypertension [8–11] or progression to hypertension [12]. Cultural aspects can also increase or decrease exposure to risk factors. The odds of obesity in LMICs is especially high for women [13], particularly in the Middle East and North Africa [14]. Sex differences for abdominal obesity start at early adolescence [15], probably due both to a preferred body image [16–18] and to food insecurity [19–22]. Education and socioeconomic inequality seem to play a role in the development of obesity [23] as well as in the access to care for hypertension [10,24–30], especially in women. Sex association of obesity in adulthood was indeed lost after accounting for education and socioeconomic factors [20,31].

Hypertension is also a determinant of chronic kidney disease (CKD), a recognized marker of the poor health outcomes of hypertension and diabetes [32]. However, growing evidence indicates that CKD is a strong cardiovascular risk factor in itself [32]. Other causes of CKD in LMICs will be discussed later on in this article. In the general population, glomerular filtration rates (GFRs) lower than 60 ml/min/1.73 m² and albuminuria (one of the earliest manifestations of CKD) were found to be associated with an independent risk of cardiovascular morbidity and mortality [33–36]. The fact that milder CKD affects 5–7% of the world population and is more common in LMICs and in disadvantaged and minority populations is worth noting [37,38]. Taken together, these findings underline the add-on role of CKD to the common recognized risk factors for global and cardiovascular mortality.

How best to respond to the rising prevalence of hypertension in resource-deprived settings is a topic of ongoing public-health debate and discussion. On the one hand, according to the Disease Control Priorities Project, two prevention strategies at population level, salt reduction and tobacco control, and a multidrug strategy to treat patients with high-risk CVD meet the condition of

cost-effectiveness multiple interventions in LMICs [39,40]. Population strategies supported by communication media with the concerted action of local authorities might induce cultural changes and the adoption of healthy lifestyle. On the other hand, WHO recommends identification of individuals with high-risk CVD in LMICs to make cost-effective the allocation of available resources. Cardiovascular risk stratification might, however, require facilities not easily available in LMICs. In 2011, the European Society of Hypertension established a Working Group on 'Hypertension and Cardiovascular risk in low resource settings', which brought together cardiologists, diabetologists, nephrologists, clinical trialists, and other stakeholders to review current strategies for cardiovascular risk assessment in population studies, their limitations, possible improvements, and future interests in screening programs. This report summarizes current evidence from the Working Group and presents highlights of unmet needs for intervention and research at patient and population levels.

PREVENTION STRATEGIES AT POPULATION LEVEL

High sodium intake has effects on BP [41–43], all-cause mortality, CVD, stroke, and coronary heart disease, which have been recently quantified by the WHO Nutrition Guidance Expert Advisory Group Subgroup on Diet and Health [44–46]. When sodium intake was less than 2 g/day, SBP was reduced by 3.47 mmHg (0.76–6.18) and DBP by 1.81 mmHg (0.54–3.08) as compared to a sodium intake \geq 2 g/day. Increased sodium intake was associated with an increased risk of stroke (risk ratio 1.24, 95% confidence interval 1.08–1.43), stroke mortality (1.63, 1.27–2.10), and coronary heart disease mortality (1.32, 1.13–1.53) [47]. Estimation of the effects of low-sodium vs. high-sodium intake on BP showed a greater increase in hypertensive and black populations than in normotensive individuals and whites, respectively [48]. The 2002 joint World Health Organization/Food and Agriculture Organization of the United Nations expert consultation [49] and the 2007 WHO guideline [50] recommend a sodium intake not greater than 2 g/day. In LMICs, tobacco consumption is increasing by 3.4% per year and smoking rates are also increasing [51,52]. In developed countries, 35% of men and 22% of women smoke, whereas in LMICs, 50% of men and 9% of women are smokers. A favorable association between smoking cessation and BP decrease over time and risk to develop hypertension in an adult sample of generally healthy men has recently been reported [53]. More than 50% of world's population now lives in urban areas where sodium consumption and tobacco use are consistently high [28,54]. Mass media campaigns have a direct impact on populations, but are expensive and require the support of local health authorities. An increasing proportion of governments in western countries have moved to ban all promotion of cigarettes and smoking via the electronic and print media [55]. Involvement of mass media-newspapers, magazines, radio, television, and films may change cultural models and help in adopting healthy lifestyle by young people. James Bond had his last cigarette in 1989 in '*Licence to kill*', but still drinks. Exposure to alcohol advertising

is strongly associated with the likelihood of adolescents starting to drink [56,57], as well as with increased alcohol consumption among young people [58,59]. Alcohol consumption increases BP values both in hypertensive and normotensive individuals [60–62]. Attention should also probably be paid on sugar in foods and beverages, an independent risk factor in LMICs for the metabolic syndrome [63].

TREATMENT STRATEGY AT THE PATIENT LEVEL

The multidrug strategy to treat patients with high cardiovascular risk also meets criteria for cost-effectiveness [39,40,64,65], and WHO fully recognizes the paradigm shift from the treatment of the single risk factor in isolation to the management of total cardiovascular risk [50,66]. Identification of patients with high-risk CVD is, thus, essential.

Cardiovascular risk stratification in low-income and middle-income countries

The first limiting factor is that facilities required to assess biochemical parameters for cardiovascular risk stratification may not be easily available in LMICs. Therefore, cardiovascular risk stratification packages proposed in 2002 by WHO were based on history, BP measurement, and selective urine analysis (performed only if BP ≥ 140 or ≥ 90 mmHg) [67]. More precisely, the WHO CVD-Risk Management Package considered three different scenarios (nonphysician health worker; medical doctor or specially trained nurse; medical doctor with access to full specialist care; Table 1) [68]. The second limitation is that most of available equations developed to predict individual absolute risk of a cardiovascular event over a specified time period [69–76] were derived from European descent populations in high-income countries and are not necessarily valid in other populations [75,77]. Therefore, WHO/International Society of Hypertension (ISH) produced specific risk prediction charts [50] using population-based standardized collection and assessment of data on risk factor prevalence and relative risk (heart attacks and stroke). Data were obtained in WHO epidemiologic subregion survey from the Comparative Risk Assessment Project [54], and in the Asia Pacific Cohort Studies Collaboration [78–82]. These charts have the same goal as existing risk equations such as those based on Framingham and SCORE [69,72]. Absolute risk of cardiovascular events was determined by scaling individual relative risk to population incidence rates of major CVDs, estimated from the GBD study [50,65,66]. WHO/ISH charts enable cardiovascular risk assessment and prediction in LMIC populations of all WHO

subregions on the basis of age, sex, SBP, type 2 diabetes mellitus, smoking status, and total serum cholesterol [50,66]. Detection of abnormalities of glucose metabolism such as impaired glucose tolerance, or the 'metabolic syndrome' is worthwhile, because some diabetes could be prevented by focused intervention on lifestyle. Screening for diabetes is more cost-effective for people in the hypertensive and obese subgroups, the costs of screening being offset in many groups by lower future treatment costs [83]. A third potential limitation is that easy obesity measurements (BMI or waist circumferences) are not included in the WHO/ISH charts, although there is strong evidence of the importance of obesity to guide intervention strategies aimed at reducing the incidence of type 2 diabetes. The global rise in overweight and obesity suggests that health promotion interventions at population level have not so far been effective, but improving lifestyles and increasing exercise in high-risk individuals remains a crucial issue. Therefore to include waist circumferences in the risk assessment could enhance awareness. Assessment of proteinuria is also not included in WHO charts, although recognizing that CVD risk may be higher than indicated in the chart in people with proteinuria.

Implementation of cardiovascular risk strategies and WHO/ISH Risk prediction charts in LMICs has different implications. First, this approach restricts unnecessary drug treatment to low-risk patients [84]. This point is especially important in LMICs where much of the costs of healthcare are currently shifted directly to patients. The WHO estimates that out of pocket expenditure of more than 15–20% can lead to impoverishment; India's proportion in 2010 was 61% [85]. Achievement of universal health coverage is a crucial step for sustainable development and for reducing poverty and social inequality, and currently represents a global goal of 'Health for all as a human right' [86]. Implementation of cardiovascular risk strategies in this context might, thus, provide a way to use limited resources more efficiently [87]. Second, the threshold of cardiovascular risk for deciding the start of drug treatment can be adjusted to suit the country context. Cost-effectiveness of an intervention indeed depends on the gross domestic product per head for the country. WHO proposed different 10-year total CVD risk thresholds for intensive intervention based on countries resource level (20% for high-resource setting; 30% for medium-resource setting; 40% for low-resource setting). Third, a little conflict with the main content may, however, exist because although cardiovascular risk stratification might be especially important for health systems of countries with very limited resources, the screening or identification of those with very high risk from the population may be much more expensive than treating only

TABLE 1. Characteristics of the three scenarios in the WHO CVD-Risk Management Package

Resource availability	Scenario 1	Scenario 2	Scenario 3
Human resources	Nonphysician health worker	Medical doctor or specially trained nurse	Medical doctor with access to full specialist care
Equipment	Stethoscope, blood pressure measurement device, measuring tape or weighing scale; Optional: test tubes, holder, burner, solution or test strips for checking urine glucose	Stethoscope, blood pressure measurement device, measuring tape or weighing scale; Test tubes, holder, burner, solution or test strips for checking urine glucose and albumin	Stethoscope, blood pressure measurement device, measuring tape or weighing scale, electrocardiograph, ophthalmoscope, urine analysis, blood analysis: fasting blood sugar, electrolytes, creatinine, cholesterol and lipoproteins

Data from [68].

hypertension. In many LMICs, facilities available for cholesterol assay are limited, although it is often feasible to check urine sugar as a surrogate measure for diabetes. In this regard, WHO/ISH charts have a second version, for use where measurement of cholesterol level is not possible [50]. If the resources are really limited, it is a preferred strategy to work only on hypertension and smoking and not on lipid and diabetes because a lower risk is attributed to them.

Despite drugs being a major contributor to healthcare costs, Mendis *et al.* [84] found that reducing the cardiovascular risk threshold for drug treatment from 30 to 20% in LMIC populations did not substantially increase the cost of treatment. Moreover, as the cardiovascular risk threshold for drug treatment is lowered, there is a concomitant increase in health benefits [67].

Cardiovascular risk assessment in population surveys

When performing population surveys in LMICs, a door-to-door approach has different advantages: data collected with a door-to-door approach allow avoiding the selection bias affecting hospital data in LMICs where universal health coverage is uncommon; the use of point-of-care instruments for biochemical assays of blood glucose and lipids, the procedure suggested by WHO, limits pre-analytical errors (storage, transportation, standardization of procedure) [88]. WHO recommends the use of affordable and reliable electronic devices for BP measurement that have the option to select manual readings [89–91]. Cost of personnel is a main component of budget in population surveys. Personnel costs and the logistic difficulties connected with organizing a two-visit strategy, therefore, lead to the adoption of a single-visit strategy in the WHO STEPwise Approach to Stroke Surveillance [92] (STEPS) aimed at assessing cardiovascular risk in populations. Although the program allows structured between countries comparison and within country follow-up of implementation of prevention strategies, its results cannot be directly transferred to cost estimation for the plan of prevention strategies. High BP is the main factor guiding cardiovascular risk stratification and the diagnosis of hypertension requires recording BP values for several days in repeated visits [93–95]. When the estimation of hypertension prevalence based on two visits was compared with the estimation

based on a single visit, the strategy adopted in the STEP program, hypertension prevalence reduced by 12% in a cohort of individuals aged 62 ± 11 years [96], by 35% in a cohort of individuals aged 39 ± 9 years [97], and by 35% in a national wide survey for the age range between 15 and 69 years (Fig. 1) [98]. Differently from what was expected, misclassification is more common at young ages, two-thirds of men less than 30 years of age having normal BP values at the second visit [98]. Thus, screening an individual at high cardiovascular risk at the first visit is crucial, but the panel of tests that can be included in surveys is to be seen in the perspective of costs. It is indeed unreliable to perform an echocardiogram in all participants in a national survey. However, the inclusion of a urine dipstick test for proteinuria in the test panel might be a sustainable approach. Proteinuria allows classifying a patient in the high or very high class of 10-year risk of cardiovascular mortality as defined by international guidelines for the management of hypertension [93–95,99,100]. When urine dipstick for proteinuria was added to the parameters included in a national survey based on two-visit assessments [98], the prevalence of individuals classified as at high or very high cardiovascular risk at the first visit remained stable at the second visit. More precisely, only 1.9% of individuals classified as at high or very high cardiovascular risk at the first visit moved to average, low or moderate cardiovascular risk categories at the second visit [98]. With this approach, a stable estimation of individuals at high cardiovascular risk could be obtained already at the first visit.

Implications for chronic kidney disease assessment in low-income and middle-income countries

In western countries, the current debated question is ‘who should be screened to make cost-effective urine dipstick for proteinuria?’. Diabetes and hypertension are the leading causes of CKD in all developed and in many developing countries [32], so that current trend is to perform a ‘selective screening’ [101,102]. WHO suggests performing urine dipstick test only if clinic BP is at least 140 or at least 90 mmHg, and dipstick test for proteinuria is not included in the WHO STEP program. However, risk factors may differ in other areas of the world [103,104] because glomerulonephritis and renal diseases of unknown causes are common in Asia




FIGURE 1 Diagnosis of hypertension (SBP ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mm Hg and/or self-reported use of antihypertensive drugs at the time of the interview) performed on the basis of measurements taken at the first visit (visit 1), at the second visit (visit 2), or both. The number of individuals with and without the condition and age-weighted rates are reported [98]. CI, confidence interval.

and sub-Saharan African countries [105]. In China, where the prevalence of proteinuria is high [106], glomerulonephritis, mainly postinfectious, is the main cause of CKD [105] and end-stage kidney disease [107–109]. Nephrotoxic effects can also result from consumption of potentially toxic herbs, incorrect substitution of harmless herbs with toxic herbs, contamination with toxic compounds, such as heavy metals, or interactions between herbs and conventional treatments [105,107,110,111]. The use of khat in Yemen was importantly associated with kidney damage (proteinuria $\geq +1$) after adjustment for several possible confounders (including hypertension and diabetes) [112]. Data collected from Nepal, Bolivia [113], and Yemen [10,112] showed that more than 5% of people younger than 60 years without previous history of diabetes and hypertension had microalbuminuria or proteinuria (Fig. 2, Table 2) [112,113]. On these bases, the Asian Forum of Chronic Kidney Disease Initiative recently suggested the addition of region-specific high-risk groups for screening, such as people exposed to harmful herbal preparations [111] or environmental factors [114]. In the absence of prospective studies performed in LMICs, it is impossible to infer that proteinuria, on a completely different background, should carry the same risk found in studies performed in industrialized societies. Likewise, although evidence for the benefits of CKD treatment with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with albuminuria combined with diabetes or CVD is strong in high-income countries [115], no randomized clinical trials have been performed in LMICs. However, integration of the urine dipstick test in screening surveys opens a perspective for sustainable cardiovascular risk assessment, and may increase health awareness in countries without advanced health systems [116]. The approach could be adapted to the conditions and socioeconomic circumstances of each nation [110].

The existing Manichean dualism of communicable and noncommunicable disease might lead physicians and researchers to disregard the evidence that some communicable diseases of children are the cause of cardiovascular events in adulthood. Rheumatic heart disease

(RHD) is still causing most of the cardiovascular morbidity and mortality in young people in different world areas [117,118]. In China, RHD is a not negligible cause of atrial fibrillation and stroke [119–121]. If RHD is detected early, monthly penicillin injections (secondary prevention) are a cost-effective means of preventing more advanced, debilitating cardiac disease [122]. Costs make stethoscope an essential equipment in cardiovascular risk stratification (Table 1), although screening programs including primary echocardiography revealed prevalence rates up to 10 times higher than those resulting from clinical examination alone [123–126]. In February 2012, the World Heart Federation published the first evidence-based criteria for echocardiographic diagnosis of RHD, and removed clinical examination from the diagnosis [127]. Ultraportable, hand-held, pocket-sized imaging devices capable of producing two-dimensional and color images are now available [128], but in LMICs, physicians and expert sonographers are scarce. The possibility that low-cost electronic stethoscope able to reach a provisional diagnosis of cardiac valve disease might be developed to screen heart murmurs in children [129] is a sector of high potential interest [130]. These devices might be accessible to unskilled personnel for screening purposes.

NEW VULNERABLE/HIGH-RISK GROUPS IN EUROPEAN UNION COUNTRIES: IMPLICATIONS FOR HEALTH SYSTEMS

In 2010, 9.4% of the total European Union populations were foreign-born [131]. Age-standardized and sex-specific stroke mortality rates in Great Britain for 1979–1983, 1989–1993, and 1999–2003 were higher for all migrant groups in each time period compared with men born in England and Wales, men born in West Africa or Bangladesh, and women from Jamaica having the highest rates. More precisely in 1999–2003, stroke mortality was almost 200% higher among male migrants from West Africa, and almost 100% higher among those from the Caribbean [132]. These findings bear similarities with the high stroke




FIGURE 2 Venn diagram showing the amount of overlap between hypertension, diabetes, and proteinuria separately for the individuals from the urban ($n=4390$) and rural area ($n=4775$). Data are expressed as percentage of urban or rural individuals, the absolute number being reported in brackets [112].

TABLE 2. Prevalence of microalbuminuria proteinuria ($\geq 1+$ at dipstick test) in participants by country

Country	ACR (ACR >30 mg/g)			Proteinuria ($\geq 1+$ at dipstick test)			Reference
	All	Women	Men	All	Women	Men	
Nepal	7.8	7.1	8.8	3.5	3.3	3.8	[113]
Bolivia	–	–	–	4.5	4.0	5.5	[113]
Georgia	–	–	–	14.0	11.6	21.5	[113]
Yemen	–	–	–	6.2	5.3	7.0	[112]
USA	10.2	11.3	9.0	–	–	–	[113]

ACR, albuminuria to creatininuria ratio.

mortality of Surinamese and Antillean-born residents in the Netherlands [133]. There is consensus that among people of African origin, hypertension is three-fold to four-fold more prevalent than the native European population [75,134–139]. With few exceptions, incidence and prevalence of diabetes mellitus are also much higher among migrants than among locally born residents [11,137,140,141]. In the UK, the incidence of end-stage renal failure among individuals from ethnic communities is three to five times greater than among the native population [142,143]. Should these data be confirmed in the different European countries, a future burden of cardiovascular (myocardial infarction and stroke) and renal disease (dialysis) can be expected in the next few decades with relevant implications in terms of costs for health systems of European Union member countries.

European Union recognized the need to improve data collection on migrants' health aimed at the creation of specific prevention policies. However, many of the European Union programs have relied on the self-report of pathological conditions. This approach was useful to limit the costs of surveys, but sound data can only be obtained by directly assessing risk factors with the adoption of standardized forms to make results comparable between countries.

Migrants from LMICs usually develop cardiovascular complications in the medium-to-long term as a consequence of different environmental circumstances [77,144–147]. Cultural adaptations have great influence on the effectiveness of interventions among specific populations [148–150]. Therefore, intervention should not be focused only on the individual, but rather on the context and community; otherwise change may not be sustainable [151].

Policy initiatives should, thus, improve data collection, to adapt organization of health systems to cultures, and to provide information to migrants on health problems and services. Europe as a whole is often perceived as a group of wealthy countries where inclusive social protection systems provide comprehensive protection for the most vulnerable [154–156]. However, in times of financial constraint, policy discussions often circle around cutting back social protection expenditures. Only four European Union member states (Netherlands, France, Portugal, and Spain) offered undocumented migrants access to primary care [131,152,153], but recent reductions in health expenditures pose severe threats and lead to decisions limiting healthcare to migrants without sufficiently investigating the impacts on

those in need [153]. A reduction in access to primary and specialist care is indeed unlikely to be cost-effective, as use of emergency services will increase [157,158]. Current budget restrictions may also widen health inequalities, hurting other population groups in the dominant ethnic groups (lower socioeconomic groups, the unemployed who comprise a very large group in Europe at present, those with limited education, and people with mental health issues) [159]. The drive to cost-effectiveness should, thus, be coupled with seeing health as an investment, avoiding myopic short-term savings through arbitrary healthcare cuts.

CONCLUSION

The clinical and epidemiological importance of CVD and high BP in LMICs markedly increased during the last decades and high BP is the leading risk factor. The establishment of culture of prevention in most LMICs requires the concerted action of television, radio, mass media-newspapers, and magazines, with the support of local health ministries and regulatory agencies, to limit salt intake and tobacco use.

Cost-effectiveness of prevention treatments at the patient level requires a cardiovascular risk approach. Identification of patients with high-risk CVD may indeed restrict unnecessary drug treatment to low-risk patients. The adoption of a cardiovascular risk approach in population surveys has also relevant implications for healthcare resource allocation decision-making. However, in low-resource settings, the screening or identification of those with very high risk from the population may be much more expensive than treating only hypertension. According to current evidence, some crucial points have to be considered both in surveys and patient care:

1. Hospital-based surveys have relevant selection bias, universal health coverage being uncommon in LMICs, so that a door-to-door approach is to be preferred;
2. Assessment of hypertension burden on the basis of a single visit may lead to overestimation of prevalence and healthcare requirements; thus survey strategies aimed at assessing global cardiovascular risk have to be considered;
3. Treatment gap is to be based on cardiovascular risk stratification (untreated individuals at high cardiovascular risk), rather than focusing on the single risk factors (untreated hypertensive patients);

4. Integration of urine dipstick test with cardiovascular health programs enhances the value of screening strategies;
5. Proteinuria and CKD in LMICs may result from post-infectious glomerulonephritis, or nephrotoxic agents so that the value of selective screening (diabetes and hypertension), currently adopted in high-income countries, might be limited in LMICs;
6. RHD still causes most of the cardiovascular morbidity and mortality in LMICs, so that the development of new strategies for optimization of the use of currently available devices (ultrasound), or the development of new low-cost device accessible to unskilled personnel to screen heart murmurs in children is a sector of high potential interest;
7. Global changes may have relevant implications for health systems of European countries, surveys exploring cardiovascular risk being now essential to focus prevention strategies in the setting of migrants and underserved communities living in Europe;
8. Intervention in the setting of migrants should not be focused only on the individual but rather on the context and community; otherwise change may not be sustainable.

ACKNOWLEDGEMENTS

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, *et al.* Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012; 380:2095–2128.
2. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, *et al.* A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012; 380:2224–2260.
3. WHO. *A global brief on Hypertension. Silent killer, global public health crisis.* Geneva, Switzerland: WHO; 2013. p. 40.
4. Ibrahim MM, Damasceno A. Hypertension in developing countries. *Lancet* 2012; 380:611–619.
5. de Villiers L, Badri M, Ferreira M, Bryer A. Stroke outcomes in a socio-economically disadvantaged urban community. *S Afr Med J* 2011; 101:345–348.
6. Walker RW, McLarty DG, Kitange HM, Whiting D, Masuki G, Mtasiwa DM, *et al.* Stroke mortality in urban and rural Tanzania. Adult Morbidity and Mortality Project. *Lancet* 2000; 355:1684–1687.
7. Johnston SC, Mendis S, Mathers CD. Global variation in stroke burden and mortality: estimates from monitoring, surveillance, and modelling. *Lancet Neurol* 2009; 8:345–354.
8. Awoke A, Awoke T, Alemu S, Megabiaw B. Prevalence and associated factors of hypertension among adults in Gondar, Northwest Ethiopia: a community based cross-sectional study. *BMC Cardiovasc Dis* 2012; 12:113.
9. Ibrahim MM, Rizk H, Appel LJ, el Aroussy W, Helmy S, Sharaf Y, *et al.* Hypertension prevalence, awareness, treatment, and control in Egypt. Results from the Egyptian National Hypertension Project (NHP). NHP Investigative Team. *Hypertension* 1995; 26:886–890.
10. Modesti PA, Bamoshmoosh M, Rapi S, Massetti L, Al-Hidabi D, Al Goshah H. Epidemiology of hypertension in Yemen: effects of urbanization and geographical area. *Hypertens Res* 2013; 36:711–717.
11. Cappuccio FP, Kerry SM, Adeyemo A, Luke A, Amoah AGB, Bovet P, *et al.* Body size and blood pressure: an analysis of Africans and the African diaspora. *Epidemiology* 2008; 19:38–46.
12. Sun Z, Zheng L, Detrano R, Zhang X, Xu C, Li J, *et al.* Risk of progression to hypertension in a rural Chinese women population with prehypertension and normal blood pressure. *Am J Hypertens* 2010; 23:627–632.
13. Black RE, Victora CG, Walker SP, Bhutta ZA, Christian P, de Onis M, *et al.* Maternal and child undernutrition and overweight in low-income and middle-income countries. *Lancet* 2013; 382:427–451.
14. Kanter R, Caballero B. Global gender disparities in obesity: a review. *Adv Nutr* 2012; 3:491–498.
15. Bamoshmoosh M, Massetti L, Aklan H, Al-Karewany M, Goshah HA, Modesti PA. Central obesity in Yemeni children: a population based cross-sectional study. *World J Cardiol* 2013; 5:295–304.
16. Holdsworth M, Delpeuch F, Landais E, Gartner A, Eymard-Duvernay S, Maire B. Knowledge of dietary and behaviour-related determinants of noncommunicable disease in urban Senegalese women. *Public Health Nutr* 2006; 9:975–981.
17. Holdsworth M, Gartner A, Landais E, Maire B, Delpeuch F. Perceptions of healthy and desirable body size in urban Senegalese women. *Int J Obes Relat Metab Disord* 2004; 28:1561–1568.
18. Duda RB, Jumah NA, Hill AG, Seffah J, Biritwum R. Assessment of the ideal body image of women in Accra, Ghana. *Trop Doct* 2007; 37:241–244.
19. Townsend MS, Peerson J, Love B, Achterberg C, Murphy SP. Food insecurity is positively related to overweight in women. *J Nutr* 2001; 131:1738–1745.
20. Chaput JP, Gilbert JA, Tremblay A. Relationship between food insecurity and body composition in Ugandans living in urban Kampala. *J Am Diet Ass* 2007; 107:1978–1982.
21. Ezzati M, Vander Hoorn S, Lawes CM, Leach R, James WP, Lopez AD, *et al.* Rethinking the ‘diseases of affluence’ paradigm: global patterns of nutritional risks in relation to economic development. *PLoS Med* 2005; 2:e133.
22. Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ, Comparative Risk Assessment Collaborating G. Selected major risk factors and global and regional burden of disease. *Lancet* 2002; 360:1347–1360.
23. Barakat H, Barakat H, Baaj MK. CVD and obesity in transitional Syria: a perspective from the Middle East. *Vasc Health Risk Manag* 2012; 8:145–150.
24. Fuentes R, Ilmanieni N, Laurikainen E, Tuomilehto J, Nissinen A. Hypertension in developing economies: a review of population-based studies carried out from 1980 to 1998. *J Hypertens* 2000; 18: 521–529.
25. Pereira M, Lunet N, Azevedo A, Barros H. Differences in prevalence, awareness, treatment and control of hypertension between developing and developed countries. *J Hypertens* 2009; 27:963–975.
26. Bovet P. Editorial: the cardiovascular disease epidemic: global, regional, local. *Trop Med Int Health* 2002; 7:717–721.
27. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. *Lancet* 2005; 365:217–223.
28. Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: a systematic review. *J Hypertens* 2004; 22:11–19.
29. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. *Circulation* 2001; 104:2746–2753.
30. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. *Circulation* 2001; 104:2855–2864.
31. Duda RB, Jumah NA, Hill AG, Seffah J, Biritwum R. Interest in healthy living outweighs presumed cultural norms for obesity for Ghanaian women. *Health Qual Life Outcomes* 2006; 4:44.
32. Couser WG, Remuzzi G, Mendis S, Tonelli M. The contribution of chronic kidney disease to the global burden of major non-communicable diseases. *Kidney Int* 2011; 80:1258–1270.
33. Meisinger C, Doring A, Lowel H, KORA Study Group. Chronic kidney disease and risk of incident myocardial infarction and all-cause and

- cardiovascular disease mortality in middle-aged men and women from the general population. *Eur Heart J* 2006; 27:1245–1250.
34. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. *Circulation* 2002; 106:1777–1782.
 35. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. *Lancet* 2010; 375:2073–2081.
 36. Fox CS, Matsushita K, Woodward M, Bilo HJG, Chalmers J, Heerspink HJL, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. *Lancet* 2012; 380:1662–1673.
 37. Barsoum RS. Chronic kidney disease in the developing world. *N Engl J Med* 2006; 354:997–999.
 38. White SL, Chadban SJ, Jan S, Chapman JR, Cass A. How can we achieve global equity in provision of renal replacement therapy? *Bull World Health Organ* 2008; 86:229–237.
 39. Gaziano TA. Cardiovascular disease in the developing world and its cost-effective management. *Circulation* 2005; 112:3547–3553.
 40. Gaziano TA, Galea G, Reddy KS. Scaling up interventions for chronic disease prevention: the evidence. *Lancet* 2007; 370:1939–1946.
 41. He FJ, Jenner KH, Macgregor GA. WASH-world action on salt and health. *Kidney Int* 2010; 78:745–753.
 42. Modesti PA, Tamburini C, Hagi MI, Cecioni I, Migliorini A, Neri Serneri GG. Twenty-four-hour blood pressure changes in young Somalian blacks after migration to Italy. *Am J Hypertens* 1995; 8:201–205.
 43. Modesti PA, Hagi MI, Corsoni V, Ferraro A, Di Vincenzo E, Vanni S, Serneri GG. Impaired adaptation of cardiopulmonary receptors to western diet in normotensive black immigrants. *Am J Hypertens* 1999; 12:145–150.
 44. Nishida C, Uauy R, Kumanyika S, Shetty P. The joint WHO/FAO expert consultation on diet, nutrition and the prevention of chronic diseases: process, product and policy implications. *Public Health Nutr* 2004; 7:245–250.
 45. Matthys F, De Backer T, De Backer G, Stichele RV. Review of guidelines on primary prevention of cardiovascular disease with aspirin: how much evidence is needed to turn a tanker? *Eur J Prev Cardiol* 2012; [Publisher online 20 December].
 46. Poole-Wilson P. The prevention of cardiovascular disease worldwide: whose task and WHO's task? *Clin Med* 2005; 5:379–384.
 47. Aburto NJ, Ziolkovska A, Hooper L, Elliott P, Cappuccio FP, Meerpohl JJ. Effect of lower sodium intake on health: systematic review and meta-analyses. *BMJ* 2013; 346:f1326.
 48. Graudal NA, Hubeck-Graudal T, Jurgens G. Effects of low-sodium diet vs. high-sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride (Cochrane Review). *Am J Hypertens* 2012; 25:1–15.
 49. Brown IJ, Tzoulaki I, Candeias V, Elliott P. Salt intakes around the world: implications for public health. *Int J Epidemiol* 2009; 38:791–813.
 50. Mendis S, Lindholm LH, Mancia G, Whitworth J, Alderman M, Lim S, Heagerty T. World Health Organization (WHO) and International Society of Hypertension (ISH) risk prediction charts: assessment of cardiovascular risk for prevention and control of cardiovascular disease in low and middle-income countries. *J Hypertens* 2007; 25:1578–1582.
 51. Hossainpoor AR, Bergen N, Kunst A, Harper S, Guthold R, Rekve D, et al. Socioeconomic inequalities in risk factors for non communicable diseases in low-income and middle-income countries: results from the World Health Survey. *BMC Public Health* 2012; 12:912.
 52. Giovino GA, Mirza SA, Samet JM, Gupta PC, Jarvis MJ, Bhala N, et al. Tobacco use in 3 billion individuals from 16 countries: an analysis of nationally representative cross-sectional household surveys. *Lancet* 2012; 380:668–679.
 53. D'Elia L, De Palma D, Rossi G, Strazzullo V, Russo O, Iacone R, et al. Not smoking is associated with lower risk of hypertension: results of the Olivetti Heart Study. *Eur J Public Health* 2013.
 54. Ezzati M, Hoorn SV, Rodgers A, Lopez AD, Mathers CD, Murray CJ, Comparative Risk Assessment Collaborating G. Estimates of global and regional potential health gains from reducing multiple major risk factors. *Lancet* 2003; 362:271–280.
 55. Jamrozik K. Population strategies to prevent smoking. *BMJ* 2004; 328:759–762.
 56. Smith LA, Foxcroft DR. The effect of alcohol advertising, marketing and portrayal on drinking behaviour in young people: systematic review of prospective cohort studies. *BMC Public Health* 2009; 9:51.
 57. Anderson P, de Bruijn A, Angus K, Gordon R, Hastings G. Impact of alcohol advertising and media exposure on adolescent alcohol use: a systematic review of longitudinal studies. *Alcohol Alcohol* 2009; 44:229–243.
 58. Jain A. Dunk that cola. *BMJ* 2013; 347:f6838.
 59. Bhaumik S. Campaign group claims that some cricketers in the Indian Premier League are breaching the rules on alcohol advertising. *BMJ* 2013; 346:f3303.
 60. McFadden CB, Brensinger CM, Berlin JA, Townsend RR. Systematic review of the effect of daily alcohol intake on blood pressure. *Am J Hypertens* 2005; 18:276–286.
 61. Koliaki C, Katsilambros N. Dietary sodium, potassium, and alcohol: key players in the pathophysiology, prevention, and treatment of human hypertension. *Nutr Rev* 2013; 71:402–411.
 62. Xin X, He J, Frontini MG, Ogden LG, Motsamai OI, Whelton PK. Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials. *Hypertension* 2001; 38:1112–1117.
 63. Malhotra A. Saturated fat is not the major issue. *BMJ* 2013; 347:f6340.
 64. Gaziano TA, Steyn K, Cohen DJ, Weinstein MC, Opie LH. Cost-effectiveness analysis of hypertension guidelines in South Africa: absolute risk versus blood pressure level. *Circulation* 2005; 112:3569–3576.
 65. Murray CJ, Lauer JA, Hutubessy RC, Niessen L, Tomijima N, Rodgers A, et al. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. *Lancet* 2003; 361:717–725.
 66. Mendis S, Lindholm LH, Anderson SG, Alwan A, Koju R, Onwubere BJC, et al. Total cardiovascular risk approach to improve efficiency of cardiovascular prevention in resource constrain settings. *J Clin Epidemiol* 2011; 64:1451–1462.
 67. Enhancing risk stratification in hypertensive subjects: how far should we go in routine screening for target organ damage? Chalmers J. . World Health Organization International - Society of Hypertension. *J Hypertens* 2002; 20:1255–1257.
 68. WHO. *WHO CVD-Risk Management Package for low- and medium-resource settings*. Geneva, Switzerland: WHO; 2002.
 69. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. *Eur Heart J* 2003; 24:987–1003.
 70. Sehestedt T, Jeppesen J, Hansen TW, Wachtell K, Ibsen H, Torp-Pedersen C, et al. Risk prediction is improved by adding markers of subclinical organ damage to SCORE. *Eur Heart J* 2010; 31:883–891.
 71. Sehestedt T, Jeppesen J, Hansen TW, Rasmussen S, Wachtell K, Ibsen H, et al. Risk stratification with the risk chart from the European Society of Hypertension compared with SCORE in the general population. *J Hypertens* 2009; 27:2351–2357.
 72. D'Agostino RB, Russell MW, Huse DM, Ellison RC, Silbershatz H, Wilson PW, Hartz SC. Primary and subsequent coronary risk appraisal: new results from the Framingham study. *Am Heart J* 2000; 139:272–281.
 73. Liu J, Hong Y, D'Agostino RB Sr, Wu Z, Wang W, Sun J, et al. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. *JAMA* 2004; 291:2591–2599.
 74. Mendis S. The contribution of the Framingham Heart Study to the prevention of cardiovascular disease: a global perspective. *Prog Cardiovasc Dis* 2010; 53:10–14.
 75. Cappuccio FP, Oakeshott P, Strazzullo P, Kerry SM. Application of Framingham risk estimates to ethnic minorities in United Kingdom and implications for primary prevention of heart disease in general practice: cross sectional population based study. *BMJ* 2002; 325:1271–1276.
 76. Hippisley-Cox J, Coupland C, Robson J, Brindle P. Derivation, validation, and evaluation of a new QRISK model to estimate lifetime risk of cardiovascular disease: cohort study using QResearch database. *BMJ* 2010; 341:c6624.

77. Brindle P, May M, Gill P, Cappuccio F, D'Agostino R Sr, Fischbacher C, Ebrahim S. Primary prevention of cardiovascular disease: a web-based risk score for seven British black and minority ethnic groups. *Heart* 2006; 92:1595–1602.
78. Woodward M, Barzi F, Martiniuk A, Fang X, Gu DF, Imai Y, *et al*. Cohort profile: the Asia Pacific Cohort Studies Collaboration. *Int J Epidemiol* 2006; 35:1412–1416.
79. Barzi F, Patel A, Gu D, Sritara P, Lam TH, Rodgers A, Woodward M, Asia Pacific Cohort Studies Collaboration. Cardiovascular risk prediction tools for populations in Asia. *J Epidemiol Community Health* 2007; 61:115–121.
80. Lawes CM, Rodgers A, Bennett DA, Parag V, Suh I, Ueshima H, *et al*. Blood pressure and cardiovascular disease in the Asia Pacific region. *J Hypertens* 2003; 21:707–716.
81. Zhang X, Patel A, Horibe H, Wu Z, Barzi F, Rodgers A, *et al*. Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. *Int J Epidemiol* 2003; 32:563–572.
82. Lawes CMM, Parag V, Bennett DA, Suh I, Lam TH, Whitlock G, *et al*. Blood glucose and risk of cardiovascular disease in the Asia Pacific region. *Diabetes Care* 2004; 27:2836–2842.
83. Waugh N, Scotland G, McNamee P, Gillett M, Brennan A, Goyder E, *et al*. Screening for type 2 diabetes: literature review and economic modelling. *Health Technol Assess* 2007; 11:143.
84. Mendis S, Lindholm LH, Anderson SG, Alwan A, Koju R, Onwubere BJ, *et al*. Total cardiovascular risk approach to improve efficiency of cardiovascular prevention in resource constrain settings. *J Clin Epidemiol* 2011; 64:1451–1462.
85. Kollannur A. Will India deliver on universal health coverage? *BMJ* 2013; 347:f5621.
86. Evans DB, Marten R, Etienne C. Universal health coverage is a development issue. *Lancet* 2012; 380:864–865.
87. Carrin G, Evans D, Xu K. Designing health financing policy towards universal coverage. *Bull World Health Organ* 2007; 85:652.
88. Lippi G, Chance JJ, Church S, Dazzi P, Fontana R, Giavarina D, *et al*. Preanalytical quality improvement: from dream to reality. *Clin Chem Lab Med* 2011; 49:1113–1126.
89. Parati G, Mendis S, Abegunde D, Asmar R, Mieke S, Murray A, *et al*. Recommendations for blood pressure measuring devices for office/clinic use in low resource settings. *Blood Press Monit* 2005; 10:3–10.
90. Parati G, Kilama MO, Faini A, Facelli E, Ochen K, Opira C, *et al*. A new solar-powered blood pressure measuring device for low-resource settings. *Hypertension* 2010; 56:1047–1053.
91. O'Brien E, Pickering T, Asmar R, Myers M, Parati G, Staessen J, *et al*. Working Group on Blood Pressure Monitoring of the European Society of Hypertension International Protocol for validation of blood pressure measuring devices in adults. *Blood Press Monit* 2002; 7:3–17.
92. Farooq MU, Chaudhry AH, Amin K, Majid A. The WHO STEPwise Approach to Stroke Surveillance. *J Coll Physicians Surg Pak* 2008; 18:665.
93. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, *et al*. 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens* 2007; 25:1105–1187.
94. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, *et al*. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens* 2013; 31:1281–1357.
95. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, *et al*. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. *Hypertension* 2003; 42:1206–1252.
96. Figueiredo D, Azevedo A, Pereira M, de Barros H. Definition of hypertension: the impact of number of visits for blood pressure measurement. *Rev Port Cardiol* 2009; 28:775–783.
97. Lang T, de Gaudemaris R, Chatellier G, Hamici L, Diene E. Prevalence and therapeutic control of hypertension in 30 000 subjects in the workplace. *Hypertension* 2001; 38:449–454.
98. Modesti PA, Rapi S, Bamoshmoosh M, Baldereschi M, Massetti L, Padeletti L, *et al*. Impact of one or two visits strategy on hypertension burden estimation in HYDY, a population-based cross-sectional study: implications for healthcare resource allocation decision making. *BMJ Open* 2012; 2:1-11.
99. Whitworth JA, World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. *J Hypertens* 2003; 21:1983–1992.
100. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, *et al*. European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). *Eur Heart J* 2012; 33:1635–1701.
101. Raffle AE, Gray JAM. *Screening: evidence and practice*. Oxford; New York: Oxford University Press; 2007.
102. Feehally J. Chronic kidney disease: health burden of kidney disease recognized by UN. *Nat Rev Nephrol* 2012; 8:12–13.
103. Perico N, Bravo RF, De Leon FR, Remuzzi G. Screening for chronic kidney disease in emerging countries: feasibility and hurdles. *Nephrol Dial Transplant* 2009; 24:1355–1358.
104. Perico N, Remuzzi G. Chronic kidney disease: a research and public health priority. *Nephrol Dial Transplant* 2012; 27 (Suppl 3):iii19–iii26.
105. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, *et al*. Chronic kidney disease: global dimension and perspectives. *Lancet* 2013; 382:260–272.
106. Zhang L, Wang F, Wang L, Wang W, Liu B, Liu J, *et al*. Prevalence of chronic kidney disease in China: a cross-sectional survey. *Lancet* 2012; 379:815–822.
107. Chen N. Chronic renal disease and dialysis in China. *Bull Acad Natl Med* 2012; 196:977–981.
108. Hou F, Jiang J, Chen J, Yu X, Zhou Q, Chen P, *et al*. China collaborative study on dialysis: a multicenters cohort study on cardiovascular diseases in patients on maintenance dialysis. *BMC Nephrol* 2012; 13:94.
109. Yao Q, Zhang W, Qian J. Dialysis status in China: a report from the Shanghai Dialysis Registry (2000–2005). *Ethn Dis* 2009; 19 (Suppl 1): S23–S26.
110. Chen N, Hsu CC, Yamagata K, Langham R. Challenging chronic kidney disease: experience from chronic kidney disease prevention programs in Shanghai, Japan, Taiwan and Australia. *Nephrology* 2010; 15 (Suppl 2):31–36.
111. Luyckx VA, Naicker S. Acute kidney injury associated with the use of traditional medicines. *Nat Clin Pract Nephrol* 2008; 4:664–671.
112. Modesti PA, Bamoshmoosh M, Rapi S, Massetti L, Bianchi S, Al-Hidabi D, Al Goshae H. Relationship between hypertension, diabetes and proteinuria in rural and urban households in Yemen. *J Hum Hypertens* 2013; 27:572–579.
113. Cravedi P, Sharma SK, Bravo RF, Islam N, Tchokhanelidze I, Ghimire M, *et al*. Preventing renal and cardiovascular risk by renal function assessment: insights from a cross-sectional study in low-income countries and the USA. *BMJ Open* 2012; 2:1–16.
114. Li PK, Chow KM, Matsuo S, Yang CW, Jha V, Becker G, *et al*. Asian chronic kidney disease best practice recommendations: positional statements for early detection of chronic kidney disease from Asian Forum for Chronic Kidney Disease Initiatives (AFCKDI). *Nephrology* 2011; 16:633–641.
115. Fink HA, Ishani A, Taylor BC, Greer NL, MacDonald R, Rossini D, *et al*. Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: a systematic review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline. *Ann Intern Med* 2012; 156:570–581.
116. Luyckx VA, Naicker S, McKee M. Equity and economics of kidney disease in sub-Saharan Africa. *Lancet* 2013; 382:103–104.
117. Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. *Lancet Infect Dis* 2005; 5:685–694.
118. Ralph AP, Carapetis JR. Group A streptococcal diseases and their global burden. *Curr Top Microbiol Immunol* 2013; 368:1–27.
119. Zhou ZQ, Hu DY, Chen J, Zhang RH, Li KB, Zhao XL. An epidemiological survey of atrial fibrillation in China. *Zhonghua Nei Ke Za Zhi* 2004; 43:491–494.
120. Zhou Z, Hu D. An epidemiological study on the prevalence of atrial fibrillation in the Chinese population of mainland China. *J Epidemiol* 2008; 18:209–216.
121. Wang D, Liu M, Hao Z, Tao W, Lin S, Zhang S, *et al*. Features of acute ischemic stroke with rheumatic heart disease in a hospitalized Chinese population. *Stroke* 2012; 43:2853–2857.

122. Darmawan J, World Health Organization-International League of Associations for Rheumatology Community-Oriented Program for the Control of Rheumatic Diseases. Recommendations from the Community Oriented Program for Control of Rheumatic Disease for data collection for the measurement and monitoring of health in developing countries. *Clin Rheumatol* 2007; 26:853–857.
123. Beaton A, Okello E, Lwabi P, Mondo C, McCarter R, Sable C. Echocardiography screening for rheumatic heart disease in Ugandan schoolchildren. *Circulation* 2012; 125:3127–3132.
124. Marijon E, Ou P, Celermajer DS, Ferreira B, Mocumbi AO, Jani D, et al. Prevalence of rheumatic heart disease detected by echocardiographic screening. *N Engl J Med* 2007; 357:470–476.
125. Carapetis JR. Rheumatic heart disease in developing countries. *N Engl J Med* 2007; 357:439–441.
126. Marijon E, Mirabel M, Celermajer DS, Jouven X. Rheumatic heart disease. *Lancet* 2012; 379:953–964.
127. Remenyi B, Wilson N, Steer A, Ferreira B, Kado J, Kumar K, et al. World Heart Federation criteria for echocardiographic diagnosis of rheumatic heart disease: an evidence-based guideline. *Nat Rev Cardiol* 2012; 9:297–309.
128. Sicari R, Gargani L, Wiecek A, Covic A, Goldsmith D, Suleymanlar G, et al. The use of echocardiography in observational clinical trials: the EURECA-m registry. *Nephrol Dial Transplant* 2013; 28:19–23.
129. DeGroff CG, Bhatikar S, Hertzberg J, Shandas R, Valdes-Cruz L, Mahajan RL. Artificial neural network-based method of screening heart murmurs in children. *Circulation* 2001; 103:2711–2716.
130. Marascio G, Modesti PA. Current trends and perspectives for automated screening of cardiac murmurs. *Heart Asia* 2013; 5:1–6.
131. Rechel B, Mladovsky P, Ingleby D, Mackenbach JP, McKee M. Migration and health in an increasingly diverse Europe. *Lancet* 2013; 381:1235–1245.
132. Harding S, Rosato M, Teyhan A. Trends for coronary heart disease and stroke mortality among migrants in England and Wales, 1979–2003: slow declines notable for some groups. *Heart* 2008; 94:463–470.
133. Stirbu I, Kunst AE, Bos V, Mackenbach JP. Differences in avoidable mortality between migrants and the native Dutch in The Netherlands. *BMC Public Health* 2006; 6:78.
134. Cappuccio FP, Cook DG, Atkinson RW, Strazzullo P. Prevalence, detection, and management of cardiovascular risk factors in different ethnic groups in south London. *Heart* 1997; 78:555–563.
135. Primates P, Bost L, Poulter NR. Blood pressure levels and hypertension status among ethnic groups in England. *J Hum Hypertens* 2000; 14:143–148.
136. Agyemang C, Bhopal R. Is the blood pressure of people from African origin adults in the UK higher or lower than that in European origin white people? A review of cross-sectional data. *J Hum Hypertens* 2003; 17:523–534.
137. Agyemang C. Trends in diabetes. *Lancet* 2007; 369:1256–1257.
138. Agyemang C, Bhopal R. Hypertension and cardiovascular disease endpoints by ethnic group: the promise of data linkage. *Heart* 2013; 99:675–676.
139. Cappuccio FP. Commentary: epidemiological transition, migration, and cardiovascular disease. *Int J Epidemiol* 2004; 33:387–388.
140. Agyemang C, Kunst AE, Bhopal R, Anujoo K, Zaninotto P, Nazroo J, et al. Diabetes prevalence in populations of South Asian Indian and African origins: a comparison of England and the Netherlands. *Epidemiology* 2011; 22:563–567.
141. Vandenheede H, Deboosere P, Stirbu I, Agyemang CO, Harding S, Juel K, et al. Migrant mortality from diabetes mellitus across Europe: the importance of socio-economic change. *Eur J Epidemiol* 2012; 27:109–117.
142. Roderick PJ, Raleigh VS, Hallam L, Mallick NP. The need and demand for renal replacement therapy in ethnic minorities in England. *J Epidemiol Comm Health* 1996; 50:334–339.
143. Lambie M, Richards N, Smith S. Ethnicity, age and incidence rates for renal replacement therapy (RRT) in Birmingham, UK: 1990–2004. *Nephrol Dial Transplant* 2008; 23:3983–3987.
144. Agyemang C, Addo J, Bhopal R, Aikins Ade G, Stronks K. Cardiovascular disease, diabetes and established risk factors among populations of sub-Saharan African descent in Europe: a literature review. *Global Health* 2009; 5:7.
145. Agyemang C, Nicolaou M, Boateng L, Dijkshoorn H, van de Born BJ, Stronks K. Prevalence, awareness, treatment, and control of hypertension among Ghanaian population in Amsterdam, the Netherlands: the GHAIA study. *Eur J Prev Cardiol* 2012; 20:938–946.
146. Beune EJ, Haafkens JA, Agyemang C, Schuster JS, Willems DL. How Ghanaian, African-Surinamese and Dutch patients perceive and manage antihypertensive drug treatment: a qualitative study. *J Hypertens* 2008; 26:648–656.
147. Yebei VN. Unmet needs, beliefs and treatment-seeking for infertility among migrant Ghanaian women in the Netherlands. *Reprod Health Matters* 2000; 8:134–141.
148. Resnicow K, Soler R, Braithwaite RL, Ahluwalia JS, Butler J. Cultural sensitivity in substance use prevention. *J Community Psychol* 2000; 28:271–290.
149. Hawthorne K, Robles Y, Cannings-John R, Edwards AG. Culturally appropriate health education for type 2 diabetes mellitus in ethnic minority groups. *Cochrane Database Syst Rev* 2008; CD006424.
150. Vlaar EMA, van Valkengoed IGM, Nierkens V, Nicolaou M, Middelkoop BJC, Stronks K. Feasibility and effectiveness of a targeted diabetes prevention program for 18 to 60-year-old South Asian migrants: design and methods of the DHIAAN study. *BMC Public Health* 2012; 12:371.
151. BeLue R, Okoror TA, Iwelunmor J, Taylor KD, Degboe AN, Agyemang C, Ogedegbe G. An overview of cardiovascular risk factor burden in sub-Saharan African countries: a socio-cultural perspective. *Global Health* 2009; 5:10.
152. Cuadra CB. Right of access to healthcare for undocumented migrants in EU: a comparative study of national policies. *Eur J Public Health* 2011; 22:267–271.
153. Greer SL, Hervey TK, Mackenbach JP, McKee M. Health law and policy in the European Union. *Lancet* 2013; 381:1135–1144.
154. Mladovsky P. A framework for analysing migrant health policies in Europe. *Health Policy (Amsterdam, Netherlands)* 2009; 93:55–63.
155. Karanikolos M, Mladovsky P, Cylus J, Thomson S, Basu S, Stuckler D, et al. Financial crisis, austerity, and health in Europe. *Lancet* 2013; 381:1323–1331.
156. MacFarlane A, O'Donnell C, Mair F, O'Reilly-de Brun M, de Brun T, Spiegel W, et al. REsearch into implementation STRategies to support patients of different ORigins and language background in a variety of European primary care settings (RESTORE): study protocol. *Implementation Sci* 2012; 7:111.
157. Mladovsky P, Rechel B, Ingleby D, McKee M. Responding to diversity: an exploratory study of migrant health policies in Europe. *Health Policy* 2012; 105:1–9.
158. Mladovsky P, Ingleby D, McKee M, Rechel B. Good practices in migrant health: the European experience. *Clin Med* 2012; 12:248–252.
159. Stuckler D, Basu S, Suhrcke M, Coutts A, McKee M. The public health effect of economic crises and alternative policy responses in Europe: an empirical analysis. *Lancet* 2009; 374:315–323.

Reviewer's Summary Evaluation

Reviewer 1

This is an interesting summary of a huge body of work and should be of interest to readers who missed the main

issue of the Lancet dealing with the Global Burden of Disease early in 2013. The main limitation is that it is not novel, but it does provide an interesting European perspective.